2023年ASCO本土创新药进展跟踪.pptx

《2023年ASCO本土创新药进展跟踪》2023 ASCOHER2CDK4/6Publication OnlyNeoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial.Pilot Trial + + +/abstracts-presentations/224842Publication OnlyPreliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).HER2/abstracts-presentations/222842Poster SessionUpdated results froma phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).II HER2 (DAP-HER-01)/abstracts-presentations/222583Poster SessionPLEASURABLE: Results and biomarkers analysis fromthe phase II study of dalpiciclib combined w ith pyrotinib and endocrine therapy (ET) in w omen w ith dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).PLEASURABLE (II ) ER+/HER2+/abstracts-presentations/222584CDK4/6Publication OnlyNeoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2- negative breast cancer.HR+/HER2-/abstracts-presentations/22484332023 ASCOPD(L)1 《2023年ASCO本土创新药进展跟踪》SHR-1701PD-L1/TGF-βSHR-1701 in combination w ith platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) forPoster Session persistent, recurrent, or metastatic cervical cancer: Data froma phase 1b/3 study.SHR-1701 BP102 Ib/III/abstracts-presentations/223074SHR-1701 SHR2554PD-L1/TGF-β EZH2Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined w ith SHR2554, an EZH2 inhibitor, in patients w ith previously treated advanced lymphoma and solid tumors.Oral Abstract Session SHR-1701(PD-L1/TGF-βRII ) SHR2554(EZH2 ) I/abstracts-presentations/220484Famitinibc-kit/VEGFR2/PDGFRβFamitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: A single-centerPoster Discussion Session exploratory study.Famitinib/abstracts-presentations/218434NANANAFUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for fir